ticker
stringlengths 2
5
| disease
stringlengths 3
196
| stage
stringclasses 15
values | date
stringlengths 19
19
| catalyst
stringlengths 18
760
| label
int64 -1
1
|
|---|---|---|---|---|---|
MITO
|
Healthy Volunteers, Rare neurodegenerative diseases
|
Phase 1
|
2022-11-01 00:00:00
|
Phase 1 data reported that treatment is generally safe and well tolerated, noted November 1, 2022.
| 1 |
CNTA
|
Hemophilia B
|
Phase 2b
|
2023-10-31 00:00:00
|
Phase 2b initiated, noted October 31, 2023.
| 0 |
KALV
|
Hereditary Angioedema (HAE)
|
Phase 1
|
2022-10-31 00:00:00
|
Phase 1 data from the study showed that the ODT tablet formulation has a similar PK profile to the film-coated version currently in development, noted October 31, 2022.
| 1 |
ARCT
|
COVID-19 vaccine
|
Phase 1/2
|
2020-12-28 00:00:00
|
Phase 1/2 data released December 28, 2020.
| 0 |
GSK
|
COVID-19 vaccine
|
Phase 2/3
|
2021-09-22 00:00:00
|
Phase 2/3 interim analysis showed primary and secondary endpoints met. 100% efficacy against severe COVID-19 & hospitalization and 84% efficacy against moderate-to-severe COVID-19 caused by any strain of SARS-CoV-2 in SPECTRA, and 79% efficacy against COVID-19 of any severity caused by the globally dominant Delta variant, noted September 22, 2021.
| 1 |
AZN
|
Paroxysmal Nocturnal Hemoglobinuria (PNH) - children
|
Approved
|
2021-06-07 00:00:00
|
FDA approval announced June 7, 2021.
| 1 |
CGTX
|
Early Alzheimer's disease
|
Phase 2
|
2023-10-27 00:00:00
|
Phase 2 data points to a role for the sigma-2 (σ-2) receptor in regulating key "housekeeping" processes such as autophagy that are impaired in Alzheimer's and other neurodegenerative diseases, noted October 27, 2023.
| 0 |
ZLAB
|
Gastrointestinal Stromal Tumors (GIST) - second-line
|
Phase 3
|
2023-06-01 00:00:00
|
Phase 3 data reported that the mPFS (90% CI) by IRR was 6.44 (2.89, 8.31) months and ORR was 21.1%, noted June 1, 2023.
| 0 |
ALLK
|
Eosinophilic Gastritis and/or eosinophilic duodenitis (EoD)
|
Phase 3
|
2022-09-09 00:00:00
|
Phase 3 24-week data showed that the company met its histologic co-primary endpoint but missed symptomatic co-primary endpoint, noted September 9, 2022.
| 1 |
IDYA
|
Solid tumors, ovarian cancer
|
Phase 1
|
2023-09-11 00:00:00
|
Phase 1 data reported tumor shrinkage observed in multiple HRD solid tumor patients, including an endometrial cancer subject with a first imaging assessment of a partial response and an 87% reduction of the CA-125 tumor marker, noted September 11, 2023.
| 1 |
ZLAB
|
Generalized Myasthenia Gravis (gMG)
|
Approved
|
2023-06-20 00:00:00
|
FDA Approved on June 20, 2023.
| 1 |
LEGN
|
Multiple myeloma
|
Approved
|
2022-02-28 00:00:00
|
Approved February 28, 2022.
| 1 |
GSK
|
Chronic rhinosinusitis with nasal polyps
|
Approved
|
2021-07-29 00:00:00
|
FDA approval announced July 29, 2021.
| 1 |
BLTE
|
Dry Age-Related Macular Degeneration (AMD)
|
Phase 2/3
|
2023-04-25 00:00:00
|
Phase 2 data reported that safe and well tolerated in adolescent Stargardt Disease (STGD1), noted April 25, 2023.
| 1 |
PFE
|
ALK+ NSCLC
|
Approved
|
2018-11-02 00:00:00
|
FDA approval announced November 2, 2018.
| 1 |
COLL
|
Pain
|
Approved
|
2015-10-25 00:00:00
|
Approved October 26, 2015.
| 1 |
APRE
|
Solid tumors
|
Phase 1/2
|
2023-10-16 00:00:00
|
Phase 1/2a data presented at AACR-NCI-EORTC reported that no dose-limiting toxicities have been reported to date with persistent tumor-reducing effect, noted October 16, 2023.
| 1 |
JNJ
|
Newly Diagnosed Multiple Myeloma (NDMM)
|
Approved
|
2019-06-28 00:00:00
|
FDA Approval announced June 28, 2019.
| 1 |
SRPT
|
Limb-girdle muscular dystrophy type 2E (LGMD2E)
|
Phase 1/2
|
2021-10-11 00:00:00
|
Results from most recent study found that treated participants (n=4, ages 4 to 7 years) improved 8.6 points on the NSAA compared to a matched natural history cohort 3 years after treatment- noted October 11, 2021.
| 1 |
JNJ
|
Plaque psoriasis
|
Approved
|
2017-10-13 00:00:00
|
Approval announced October 13, 2017.
| 1 |
GSK
|
Chronic obstructive pulmonary disease (COPD)
|
Approved
|
2017-09-18 00:00:00
|
Approval announced September 18, 2017.
| 1 |
IMMP
|
Melanoma
|
Phase 1
|
2018-05-30 00:00:00
|
Phase 1 data released May 30, 2018 showed ORR of 61% (11/18 patients).
| 1 |
TCON
|
Wet age-related macular degeneration (Wet-AMD)
|
Phase 2
|
2020-03-09 00:00:00
|
Development to be discontinued - March 9, 2020.
| -1 |
ENTA
|
HCV - genotype 1
|
Approved
|
2014-12-19 00:00:00
|
Approved December 19, 2014.
| 1 |
SGEN
|
Squamous cell carcinoma of the head and neck (SCCHN)
|
Phase 2
|
2023-04-17 00:00:00
|
Phase 2 interim results presented at AACR reported a confirmed ORR of 40%, with one complete response and 5 partial responses, noted April 17, 2023.
| 1 |
NVCR
|
Mesothelioma
|
Phase 2
|
2018-04-17 00:00:00
|
Phase 2 top-line data released April 17, 2018 noted improvements in overall survival and progression free survival. Data to be presented at upcoming conference.
| 1 |
IONS
|
Immunoglobulin A nephropathy (IgAN)
|
Phase 2
|
2022-11-07 00:00:00
|
IONIS-FB-LRx achieved a 44% mean reduction in proteinuria in patients treated for 6 months
| 1 |
NCNA
|
Solid tumors
|
Phase 2
|
2023-10-16 00:00:00
|
Phase 1/2 part 2 for both as a monotherapy in solid tumors and in combination with the anti-PD-1 therapy pembrolizumab in patients with metastatic cutaneous melanoma showed that treatment has been well tolerated both as a monotherapy and in combination with pembrolizumab. Encouraging signs of efficacy, including tumor volume reductions and prolonged time on treatment have been observed in both the monotherapy and combination cohorts, noted October 16, 2023.
| 1 |
ZURA
|
Primary Sjogren's Syndrome
|
Phase 2
|
2022-01-27 00:00:00
|
Phase 2 study withdrawn noted January 27, 2022.
| 0 |
EFTR
|
relapsed/refractory Acute Myeloid Leukemia (AML)
|
Phase 1
|
2023-10-24 00:00:00
|
Phase 1 initiated, noted October 24, 2023.
| 0 |
VIGL
|
Adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP)
|
Phase 1
|
2023-09-11 00:00:00
|
Phase 2 data analysis demonstrated that VGL101 continued to have a favorable safety and tolerability profile and proof-of-target engagement in SAD/MAD cohorts up to 60 mg/kg with six-month interim data expected 4Q 2023, noted Septemeber 11, 2023.
| 1 |
KA
|
Solid tumors
|
Phase 1/2
|
2023-11-03 00:00:00
|
Phase 1/2 biomarker data to be presented at SITC, noted Noember 3 2023.
| 1 |
MOR
|
Plaque psoriasis
|
Approved
|
2019-02-27 00:00:00
|
Approval announced February 27, 2019.
| 1 |
ESPR
|
LDL-C and type 2 diabetes
|
Phase 2
|
2019-08-28 00:00:00
|
Phase 2 data met primary endpoint.
| 0 |
JNJ
|
Relapsed or refractory (R/R) multiple myeloma.
|
Approved
|
2022-10-26 00:00:00
|
Approved October 26, 2022.
| 1 |
VRDN
|
Thyroid Eye Disease (TED)
|
Phase 1/2
|
2023-04-27 00:00:00
|
Phase 1/2 clinical data reported that 80% (4/5) of VRDN-001 responders showed durability of effects at 12 weeks, noted April 27, 2023.
| 1 |
CYAD
|
Colorectal cancer
|
Phase 1b
|
2022-03-02 00:00:00
|
Phase 1b trial initiated December 16, 2021. Phase 1b trial voluntarily paused due to reports of two fatalities that presented with similar pulmonary findings, noted February 28, 2022. Clinical hold announced.
| 1 |
ATAI
|
Healthy volunteers
|
Phase 1
|
2023-08-08 00:00:00
|
Phase 1 was generally well-tolerated with no SAE reported. At the 60mg IV dose, rates of sedation and dissociation were consistent with prior studies of PCN-101 at this dose-level, noted August 8, 2023.
| 1 |
INCY
|
Cancer - first-line metastatic melanoma
|
Phase 3
|
2018-04-06 00:00:00
|
Phase 3 trial did not meet primary endpoint - noted April 6, 2018.
| 1 |
ADCT
|
Diffuse Large B-Cell Lymphoma
|
Phase 2
|
2023-06-09 00:00:00
|
Phase 2 data presented at EHA showed that 31% of patients who achieved a complete response remained event-free for two or more years and did not need new anticancer therapy, noted June 9, 2023.
| 1 |
MRK
|
Head and neck squamous cell carcinoma (HNSCC)
|
Phase 2
|
2021-11-09 00:00:00
|
Phase 2 clinical data showed that patients with 1L HNSCC who have not received prior treatment for their advanced disease (n=13), the dose demonstrates an initial ORR of 38.5% with a 12-month OS rate of 87.5% and mOS not reached in combination with pembrolizumab + 5FU + platinum. These results compare favorably with benchmark survival data from standard pembrolizumab + chemotherapy, noted November 9, 2021.
| 1 |
SLDB
|
Duchenne Muscular Dystrophy
|
Phase 1/2
|
2022-03-14 00:00:00
|
Phase 1/2 2-year data from first three patients in the high dose (2E14 vg/kg) cohort suggest sustained or improved motor function, pulmonary function and clinically validated patient-reported outcomes compared with expected declines reported by natural history data, noted March 14, 2022.
| 1 |
BMY
|
Renal Cell Carcinoma (RCC)
|
Phase 3
|
2022-09-08 00:00:00
|
Phase 3 data presented at ESMO reported that the median PFS was not reached for the triple combination and was 11.3 months for the combination of nivolumab and ipilimumab. Objective response rates in the PFS intent-to-treat population was 43% and 36%, respectively, noted September 8, 2022.
| 1 |
TEVA
|
Rituxan (rituximab) biosimilar
|
Approved
|
2018-11-28 00:00:00
|
FDA Approval announced November 28, 2018.
| 1 |
EDIT
|
Leber Congenital Amaurosis type 10 (LCA10)
|
Phase 1/2
|
2021-09-29 00:00:00
|
Phase 1/2 initial data displayed 2 (66%) subjects in the mid-dose cohort showed improvements in BCVA, FST, and/or mobility navigation. However, retinal tears were reported by 2 (50%) subjects, 1 report of hypotony in the low dose cohort, as well as 1 retinal hemorrhage. Treatment in the adult high-dose cohort continues and pediatric mid-dose cohort commencing September 29, 2021.
| 1 |
LLY
|
Obesity
|
Phase 2
|
2023-06-24 00:00:00
|
Phase 2 met primary and secondary endpoints, noted June 24, 2023.
| 0 |
ZNTL
|
Ovarian cancer
|
Phase 1b
|
2023-06-05 00:00:00
|
Phase 1b dose escalation data presented at ASCO reported that confirmed ORR of 50.0% and mPFS of 7.4 months in combination with paclitaxel, and a confirmed ORR of 35.7% and mPFS of 10.4 months in combination with carboplatin, noted June 5, 2023.
| 1 |
GRTS
|
1L Microsatellite-Stable Colorectal Cancer (MSS-CRC)
|
Phase 1/2
|
2022-01-13 00:00:00
|
Phase 1/2 data demonstrated that patients who experienced a molecular response, continue to have an OS advantage compared to those patients who did not have a molecular response. All patients alive at the time of the ESMO 2021 data presentation remain alive after an additional 22 weeks of follow-up, noted January 13, 2021.
| 1 |
IPSEY
|
Alagille syndrome (ALGS)
|
Approved
|
2023-06-13 00:00:00
|
FDA Approved on June 13, 2023.
| 1 |
ETNB
|
Nonalcoholic steatohepatitis (NASH)
|
Phase 1/2
|
2022-06-27 00:00:00
|
Additional Phase 1b/2a data presented at EASL reported that in the cohort of NASH subjects PGZ led to a meaningful reductions in extra-hepatic metabolic parameters, noted June 27, 2022.
| 1 |
ASMB
|
Hepatitis B
|
Phase 1a
|
2023-04-18 00:00:00
|
Phase 1a clinical data for the remaining 200 mg multiple dose cohort for ABI-4334 continue to demonstrate encouraging clinical profile with strong projected activity against both viral replication and cccDNA formation, noted April 18, 2023.
| 1 |
RHHBY
|
Duchenne Muscular Dystrophy
|
Approved
|
2023-06-22 00:00:00
|
FDA acelerated Approval on June 22, 2023.
| 1 |
TBPH
|
Gastroparesis
|
Phase 2b
|
2017-08-02 00:00:00
|
Phase 2b data released August 2, 2017. Primary endpoint not met.
| 0 |
PFE
|
Recurrent renal cell carcinoma (RCC)
|
Phase 3
|
2018-04-10 00:00:00
|
Phase 3 trial discontinued due to futility.
| -1 |
ALBO
|
Nonalcoholic steatohepatitis (NASH)
|
Phase 2
|
2020-08-18 00:00:00
|
Phase 2 trial met primary endpoint. However, development in NASH will not continue - August 18, 2020.
| 0 |
ASMB
|
Hepatitis B virus (HBV)
|
Phase 2
|
2022-11-01 00:00:00
|
Phase 2 preliminary data from 65 patients randomized to receive AB-729+VBR+NA (n=32), AB-729+NA (n=17) or VBR+NA (n=16) for 48 weeks showed that adding VBR to AB-729+NA does not result in greater on-treatment improvements in markers of HBV infection as compared to AB-729+NA alone, noted November 1, 2022.
| 1 |
RLYB
|
Fetal and neonatal alloimmune thrombocytopenia (FNAIT)
|
Phase 1b
|
2023-06-24 00:00:00
|
Phase 1b data presented at ISTH showed that subcutaneous administration produced a dose-dependent, rapid and complete elimination of transfused HPA-1a positive platelets in HPA-1a negative subjects, with both doses meeting the prespecified proof-of-concept criteria of ≥90% reduction in mean platelet elimination half-life. Mean platelet elimination half-life was 5.8 hours (0.09mg) and 1.5 hours (0.29mg) for RLYB212 compared to 71.7 hours for placebo, noted June 24, 2023.
| 1 |
TGTX
|
Chronic Lymphocytic Leukemia
|
Phase 1/2
|
2021-09-20 00:00:00
|
Phase 1/2 data demonstrated that 47 patients have now been treated as of the data cutoff with 57% of patients previously exposed to a BTK inhibitor, best Overall Response Rate (ORR) was 100% amongst evaluable patients (n=46), including 37% complete response (CR) rate presented at iwCLL September 20, 2021.
| 1 |
NCNA
|
2L Colorectal cancer
|
Phase 2
|
2023-10-13 00:00:00
|
Phase 2 patients recruiting well with no new safety signals, noted October 13, 2023.
| 0 |
REGN
|
Coronavirus COVID-19
|
Phase 3
|
2020-09-01 00:00:00
|
Phase 3 global trial did not meet primary endpoint - September 1, 2020.
| 1 |
MYOV
|
Advanced prostate cancer
|
Approved
|
2020-12-18 00:00:00
|
FDA approval announced Decmber 18, 2020.
| 1 |
SLS
|
Malignant pleural mesothelioma (MPM)
|
Phase 1
|
2023-06-28 00:00:00
|
Phase 1 topline data reported that the median overall survival for patients who entered the study as Stage IV patients was 62.3 weeks, noted June 28, 2023.
| 0 |
AZN
|
Small cell lung cancer (SCLC)
|
Phase 3
|
2021-09-18 00:00:00
|
Phase 3 data showed sustained efficacy after a median follow up of more than three years, with a 29% reduction in the risk of death versus chemotherapy alone. Updated median OS was 12.9 months versus 10.5 for chemotherapy. 17.6% of patients treated with IMFINZI plus chemotherapy were alive at three years, versus 5.8% of patients treated with chemotherapy alone, September 18, 2021.
| 1 |
PFE
|
Transthyretin amyloid cardiomyopathy (ATTR-CM)
|
Approved
|
2019-05-06 00:00:00
|
FDA approval announced May 6, 2019.
| 1 |
AMGN
|
Alzheimer’s Disease
|
Phase 2/3
|
2019-07-11 00:00:00
|
Phase 2/3 trial discontinued due to lack of efficacy.
| -1 |
ETON
|
Nutritional deficiencies
|
CRL
|
2020-11-12 00:00:00
|
CRL received October 2020 (announced November 12, 2020).
| 0 |
ZYME
|
HER2-positive Gastroesophageal Adenocarcinoma (GEA)
|
Phase 2
|
2021-09-16 00:00:00
|
Phase 2 data showed confirmed objective response rate (cORR) of 75% and disease control rate (DCR) of 89% overall, with a cORR of 93% and DCR of 100% in the proposed Phase 3 regimen noted September 16, 2021.
| 1 |
PFE
|
Postherpetic neuralgia (PHN)
|
Approved
|
2017-10-12 00:00:00
|
Approval announced October 12, 2017.
| 1 |
DRRX
|
Post-operative pain relief
|
Approved
|
2021-02-02 00:00:00
|
FDA approval announced February 2, 2021.
| 1 |
MCRB
|
Mild-to-Moderate Ulcerative Colitis
|
Phase 2b
|
2021-12-16 00:00:00
|
Phase 2b microbiome analyses reported engraftment and anticipated changes in disease-relevant metabolites post-administration were not observed, noted December 16, 2021.
| 1 |
MNPR
|
Soft tissue sarcoma
|
Phase 1b
|
2023-11-01 00:00:00
|
t, as well, which may result in further tumor size reduction, noted August 8, 2023. Phase 1b data showed that 9 out of the 14 patients have had stable disease (SD, as defined by RECIST 1.1 criteria) after camsirubicin treatment., noted November 1, 2023.
| 1 |
INCY
|
Atopic dermatitis
|
Approved
|
2021-09-21 00:00:00
|
Approved September 21, 2021.
| 1 |
NYMX
|
Benign prostatic hyperplasia (BPH)
|
Phase 3
|
2015-07-27 00:00:00
|
Phase 3 endpoints met in extension trial July 2015.
| 0 |
BCYC
|
Solid tumors
|
Phase 1/2
|
2022-09-06 00:00:00
|
Phase 1/2 dose escalation cohort data reported an overall response rates of 22% and 67% in ovarian and urothelial cancers, with one complete response, noted September 7, 2022.
| 0 |
ABBV
|
Preventive treatment of migraine
|
Approved
|
2023-04-18 00:00:00
|
Approved April 17, 2023.
| 1 |
BGNE
|
Cervical Cancer (CC)
|
Phase 2
|
2023-10-22 00:00:00
|
Phase 2 data presented at ESMO reported that the ORR was 22.5%, with 13 complete responses; 76.8% had a durable response of ≥6 mo, noted October 22, 2023.
| 1 |
URGN
|
Overactive Bladder (OAB)
|
Phase 2
|
2020-08-27 00:00:00
|
Phase 2 trial did not meet primary endpoint - August 27, 2020.
| 1 |
CLLS
|
Multiple myeloma
|
Phase 1/2
|
2021-12-13 00:00:00
|
Additional Phase 1/2 data noted a 71% overall response rate (ORR) and that 46% of patients achieved a very good partial response or better (VGPR+) including 25% complete response or stringent complete response (CR/sCR), noted December 13, 2021.
| 1 |
VNDA
|
Insomnia
|
Approved
|
2014-01-31 00:00:00
|
Approved January 31, 2014.
| 1 |
NVCR
|
Recurrent glioblastoma
|
Phase 2
|
2022-12-12 00:00:00
|
Phase 2 trial data reported that median progression-free survival was 4.5 months compared to 2.2 months in the historical control, noted December 12, 2022.
| 0 |
REGN
|
Multiple myeloma
|
Phase 2
|
2022-12-12 00:00:00
|
Phase 2 data reported a 64% response rate, with 45% of responders achieving a very good partial response or better, noted December 12, 2022.
| 1 |
ATRA
|
Epstein-Barr virus (EBV-PTLD) after solid organ transplant (SOT)
|
Phase 3
|
2021-11-04 00:00:00
|
Phase 3 data reported a 50% objective response rate (ORR), noted November 4, 2021.
| 0 |
MDNA
|
Recurrent Glioblastoma (GBM)
|
Phase 2b
|
2023-07-20 00:00:00
|
Phase 2b trial published in the journal Neuro-Oncology, and when compared to a well-matched external control, bizaxofusp more than doubled the median survival in end-stage rGBM patients, noted July 20, 2023. Phase 3 trial planned.
| 0 |
EGRX
|
Chronic lymphocytic leukemia; Indolent non-Hodgkin's lymphoma - cancer
|
Approved
|
2014-07-02 00:00:00
|
Tentative approval July 2 2014. Teva has also received orphan drug and related pediatric exclusivity expiring in September 2015 and May 2016 for the CLL and NHL indications, respectively.
| 1 |
BBIO
|
Limb Girdle Muscular Dystrophy Type 2i (LGMD2i)
|
Phase 2
|
2023-10-09 00:00:00
|
Phase 2 long-term data at Month 21 demonstrate a well-tolerated safety profile, and stabilization in 10 meter walk test (10MWT), 100-m timed test (100mTT), and the North Star Assessment (NSAD) scores, noted October 9, 2023.
| 1 |
AIMD
|
Sjögren's syndrome
|
Phase 3
|
2022-11-03 00:00:00
|
Phase 3 results showed increased unstimulated whole saliva and improvements in mouth dryness and seven other SS symptoms, noted November 3, 2022.
| 1 |
JNJ
|
HIV in Women
|
Phase 2b
|
2021-08-31 00:00:00
|
Phase 2b data did not meet endpoints, study will not continue - August 31, 2021.
| 1 |
ATHX
|
Acute Respiratory Distress Syndrome
|
Phase 2
|
2021-08-06 00:00:00
|
Phase 2 open-label data released August 6, 2021. 20/28 days were ventilator free compared with 11/28 for standard therapy.
| 0 |
NKTR
|
Bronchiectasis
|
Phase 3
|
2017-04-05 00:00:00
|
Phase 3 second trial did not meet endpoint - April 5, 2017.
| 1 |
IONS
|
ATTR cardiomyopathy
|
Phase 3
|
2023-07-31 00:00:00
|
Phase 3 trial initiation announced January 10, 2020. Phase 3 enrollment completed, noted July 31, 2023.
| 0 |
IMGO
|
Essential Thrombocythemia
|
Phase 2
|
2022-12-12 00:00:00
|
Phase 2 data reported that 100% of patients treated with bomedemstat for ≥24 weeks achieved a platelet count in the normal range and 89% (25/28) achieved a durable (≥12 weeks) platelet count, noted December 12, 2022.
| 1 |
CINC
|
Treatment Resistant Hypertension (rHTN)
|
Phase 2
|
2022-11-07 00:00:00
|
Phase 2 presentation at AHA reported that iomarker activity clinically demonstrate how baxdrostat mechanistically achieves selective blood pressure lowering effects with no impact on cortisol, noted November 7, 2022.
| 1 |
GILD
|
HIV
|
Phase 2/3
|
2022-02-16 00:00:00
|
Phase 2/3 one-year results reported that 83%of participants receiving lenacapavir in combination with an optimized background regimen achieved an undetectable viral load at Week 52, noted February 16, 2022.
| 1 |
PFE
|
Alzheimer’s disease
|
Phase 2/3
|
2021-01-18 00:00:00
|
Phase 2/3 top-line data did not meet co-primary endpoints - January 18, 2021.
| 1 |
HARP
|
Small cell lung cancer
|
Phase 1/2
|
2023-10-23 00:00:00
|
Phase 1/2 data from ESMO reported a confirmed response rate 35% (11/31), across all tumor types and patient cohorts treated with 1 mg priming dose, and a 32% (6/19) confirmed response rate in patients with small cell lung cancer (SCLC), noted October 23, 2023.
| 1 |
ITRM
|
Complicated urinary tract infections (cUTI)
|
Phase 3
|
2020-06-01 00:00:00
|
Phase 3 data did not meet primary endpoint - June 1, 2020.
| 1 |
FSTX
|
Head and neck cancer
|
Phase 2
|
2022-08-11 00:00:00
|
Phase 2 data reported that treatment was well tolerated and cleared the pre-determined futility, noted August 11, 2022.
| 1 |
OTIC
|
Meniere's disease
|
Phase 3
|
2017-08-30 00:00:00
|
Phase 3 data released August 30 failed to meet primary and key secondary endpoints.
| 1 |
LLY
|
Obesity or overweight with weight-related comorbidities
|
Phase 3
|
2023-07-27 00:00:00
|
Phase 3 trial met both co-primary endpoints, noted July 27, 2023.
| 0 |
TOVX
|
Head and Neck Squamous Cell Carcinoma
|
Phase 1
|
2023-10-23 00:00:00
|
Phase 1 data shared at ESMO 23 showed enhanced patient survival, correlating with VCN-01 mediated increases in the CPS score, a key determinant of outcomes with anti-PD-(L)1 checkpoint inhibitor therapies, noted October 23, 2023.
| 1 |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.